

BD tools for vaccine combination
product developers

BD Effivax™ Glass Prefillable Syringe



BD Effivax™ is a single use Sterile Clean and Ready to Fill syringe (BD SCF™), designed for manual intramuscular or subcutaneous injection of medical products for the Vaccines market segment¹

BD Effivax™ configuration

Talk to your
BD representative
about options for
customization

Volume	1 mL
Flange design	Round
Tip cap	PRTC FM30

Key benefits

- **New vaccine syringe platform,** carrier for future innovation
- **A step forward in luer lock PFS performance as compared to previous generation BD vaccine PFS*:**
 - Overall integrity improved due to the reduction of cracks and contamination specifications¹
 - Stricter glass particles specification¹
 - 100%-dimensional controls (ISO11040-4)
 - Stricter visible cosmetic defects specifications¹
 - Control plan harmonized across manufacturing sites for product consistency³
- **Estimated to improve Total Cost of Ownership (TCO) by 2%⁴**
 - Filling and packing optimized, consequently minimizing line stops
- **Batch performance documentation (CoA)**
- **Broad range of value-added services*****
 - Regulatory expertise in combination product
 - Functional tests in c-GMP compliant labs
 - E&L studies with toxicological assessment
- **Multi-sourcing network options for business continuity:**
 - 2 plants : in Europe and in North America

Experience

- Assessed by a major pharmaceutical manufacturer⁴
- BD Effivax™ is built on years of BD's expertise partnering with leading pharmaceutical companies⁵,⁶
- BD is uniquely positioned with high volume production capacity delivering hundreds of millions of PFS for vaccines each year⁶

Availability

- Non For Human Use (NFHU) samples available on demand
- Commercial availability to be evaluated against requirements
- Will benefit from BD long-term capacity extension program with investment of over USD 1.2 billion for ready to fill containers for injectable drugs⁷

* Compared with BD Hypak™ for Vaccines;

** BD Visioguard™: features 100% automated visual inspection to identify defects and support operational excellence;

***Non exhaustive list; CoA : Certificate of Analysis; c-GMP: Current Good Manufacturing Practices; E&L: Extractables and Leachables



References

1. BD internal reference, Customer Quality Specification BD Effivax™ SC000243, BD Hypak™ for Vaccine SC000110, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
2. BD internal reference, Global Product Manufacturing Specification 442.GPMS.060, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
3. BD internal analysis, TCO Model, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
4. BD sales analysis [internal analysis]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2022
5. Vaccines Market Size, Share & COVID-19 Impact Analysis, Market Research Report, <https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769>, February 2022
6. BD sales analysis [internal analysis]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2021
7. BD-PS external communication to customers - BD to Invest \$1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years. <https://news.bd.com/2020-12-02-BD-to-Invest-1-2-Billion-in-Pre-Fillable-Syringe-Manufacturing-Capacity-Over-Next-Four-Years> . Accessed Dec. 2, 2020

BD Medical

Pharmaceutical Systems

United States

1 Becton Drive

Franklin Lakes, NJ 07417

+1 800 225 3310

Europe

11 rue Aristide-Bergès

38800 Le Pont-de-Claix

France

Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05

Becton Dickinson France S.A.S - Share capital: 64 719 915 €

RCS Grenoble B 056 501 711

bd.com

